---
title: "Isatuximab"
slug: "isatuximab"
date: "2023-12-09"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ªï¼š[[Monoclonal Antibodies]] and [[treatment of multiple myeloma (MM)]]

# Isatuximab

Isa**TU**ximab

[Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma | New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2400712)

---

- Design: Phase III randomized trial
- Number of patients: 446
- Patients characteristics: Not specified
- Agent: Isatuximab-VRd group (isatuximab with bortezomib, lenalidomide, and dexamethasone) vs VRd group (bortezomib, lenalidomide, and dexamethasone). Specific doses not provided.
- Treatment line: Not specified
- Trial Acronym IMROZ

> è³½è«¾è²å®‰è¬ç‰¹çš„ IMROZ ç¬¬ 3 æœŸç ”ç©¶é¡¯ç¤º Sarclisa èˆ‡ VRd è¯ç”¨ï¼Œå¯å°‡æ–°è¨ºæ–·çš„ç„¡æ³•ç§»æ¤å¤šç™¼æ€§éª¨é«“ç˜¤æ‚£è€…çš„ç–¾ç—…é€²å±•æˆ–æ­»äº¡é¢¨éšªé™ä½ 40ï¼…ï¼Œé€™æ˜¯å…¨çƒé¦–å€‹ç”¨ VRd è¯åˆæŠ— CD38 çš„ç¬¬ 3 æœŸç ”ç©¶ï¼Œä»¥æ”¹å–„ PFS

---

- Comparison of efficacy:

|                                                 | Isatuximab-VRd group | VRd group |
| ----------------------------------------------- | -------------------- | --------- |
| PFS at 60 months (%)                            | 63.2%                | 45.2%     |
| CR or better (%)                                | 74.7%                | 64.1%     |
| MRD-negative status and a complete response (%) | 55.5%                | 40.9%     |

- Highlight of toxicity: No new safety signals observed with the isatuximab-VRd regimen. Incidence of serious adverse events and adverse events leading to discontinuation were similar in both groups.
- One line summary:
  - Isatuximab-VRd regimen showed superior efficacy in terms of progression-free survival, complete response rate, and MRD-negative status compared to VRd regimen with similar safety profiles.
